Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Thomas Zeyen - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Laura Böhm - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Daniel Paech - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Niklas Schäfer - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Theophilos Tzaridis - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Cathrina Duffy - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Louisa Nitsch - , Universitätsklinikum Aachen (Autor:in)
  • Matthias Schneider - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Anna-Laura Potthoff - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Javen Lennard Schneider-Rothhaar - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Joachim Peter Steinbach - , Universitätsklinikum Frankfurt (Autor:in)
  • Peter Hau - , Universitätsklinikum Regensburg (Autor:in)
  • Thomas Kowalski - , BG Universitätsklinikum Bergmannsheil Bochum (Autor:in)
  • Clemens Seidel - , Universitätsklinikum Leipzig (Autor:in)
  • Dietmar Krex - , Klinik und Poliklinik für Neurochirurgie (Autor:in)
  • Oliver Grauer - , Universitätsklinikum Münster (Autor:in)
  • Roland Goldbrunner - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Pia Susan Zeiner - , Universitätsklinikum Frankfurt (Autor:in)
  • Ghazaleh Tabatabai - , Universitätsklinikum Tübingen (Autor:in)
  • Norbert Galldiks - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Walter Stummer - , Universitätsklinikum Münster (Autor:in)
  • Elke Hattingen - , Universitätsklinikum Frankfurt (Autor:in)
  • Martin Glas - , Deutsches Konsortium für Translationale Krebsforschung (DKTK) - Essen / Düsseldorf (Autor:in)
  • Eleni Gkika - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Hartmut Vatter - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Alexander Radbruch - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Ulrich Herrlinger - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Johannes Weller - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)
  • Christina Schaub - , Centrum für Integrierte Onkologie (CIO) Aachen Bonn Cologne Duesseldorf (Autor:in)

Abstract

BACKGROUND: Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The RANO resect group recently proposed criteria for volumetry-based EOR assessment in patients that were treated according to Stupp´s protocol. The purpose of this study was (1) to investigate the prognostic value of EOR in patients receiving combined chemotherapy with lomustine (CCNU)/temozolomide (TMZ), and (2) to analyse the prognostic performance of binary EOR assessment compared to volumetric assessment.

METHODS: 78 patients with newly diagnosed MGMT-methylated GBM undergoing tumor resection followed by radiochemotherapy with CCNU/TMZ were included in this study. Residual contrast-enhancing (CE) tumor volume after the first resection was measured and its influence on OS and PFS was analysed using uni- and multivariable Cox regression analysis as well as two-sided log rank test. Patients were divided into RTV ≤1 cm³, >1 cm³ - ≤5 cm³ and >5 cm³ following the proposed criteria of the RANO resect group.

RESULTS: Prolonged OS was associated with age <60 years, low RTV, and gross total resection (GTR). Residual tumor volume (RTV) had a superior prognostic value compared to binary EOR assessment. Patients with total or near total resection of CE tumor (≤1 cm³ RTV) showed prolonged OS (median 54.4 months, 95% CI 46.94-not reached), with a 5-year survival rate of 49%.

CONCLUSION: Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.

Details

OriginalspracheEnglisch
Seiten (von - bis)557-566
Seitenumfang10
FachzeitschriftNeuro-oncology
Jahrgang27
Ausgabenummer2
Frühes Online-Datum1 Okt. 2024
PublikationsstatusVeröffentlicht - 1 Feb. 2025
Peer-Review-StatusJa

Externe IDs

unpaywall 10.1093/neuonc/noae205
Scopus 85217850045
Mendeley f712b0ff-e420-379b-b44c-10410374e4e5

Schlagworte

Schlagwörter

  • Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain Neoplasms/mortality, Chemoradiotherapy/mortality, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes, Female, Follow-Up Studies, Glioblastoma/mortality, Humans, Lomustine/administration & dosage, Male, Middle Aged, Neoplasm, Residual/mortality, Prognosis, Retrospective Studies, Survival Rate, Temozolomide/therapeutic use, Young Adult